Completed PHASE4 INTERVENTIONAL 2-arm NCT00545909

BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis

A Randomised, Open Label Study to Investigate the Impact of Bone Marker Feedback at 2 Months on Adherence to Monthly Oral Bonviva (Ibandronate) in Women With Post-menopausal Osteoporosis.

Sponsor: Hoffmann-La Roche

Conditions Postmenopausal Osteoporosis

Interventions ibandronate [Bonviva/Boniva]

Updated 7 times since 2017 Last updated: Nov 1, 2016 Started: Mar 31, 2006 Primary completion: Aug 31, 2008 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00545909, this PHASE4 trial focuses on Postmenopausal Osteoporosis and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE4
Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalst, Belgium , Antwerp, Belgium , Athens, Greece , Aye, Belgium , Braine-l'Alleud, Belgium , Bregenz, Austria , Bruges, Belgium , Brussels, Belgium , Charleroi, Belgium , Dinant, Belgium and 32 more locations